Regulus Therapeutics Continues Its Uptrend After Positive Data In Early Hepatitis C Study
October 24, 2014 at 15:19 PM EDT
Shares of Regulus Therapeutics (RGLS) soared as much as 100% in one trading session after the company released some early data for their Hepatitis C drug.
